In Vivo 9.4 Tesla MRI Imaging in Drug-Resistant Epilepsy: Technical Overview
Overview
This report presents the first in vivo 9.4T MRI imaging in a patient with drug-resistant epilepsy (DRE) who was MRI-negative at 3T and 7T. The 9.4T MRI demonstrated superior spatial resolution and improved visualization of mesiotemporal and cortical structures relevant for epilepsy diagnosis, despite technical challenges related to field inhomogeneities and SAR.
Background
Epilepsy affects approximately 68 million people worldwide, with 30–40% of focal epilepsy patients exhibiting drug-resistant epilepsy (DRE). Surgical treatment efficacy depends on accurate localization of epileptogenic lesions, which are often undetectable on standard 3T MRI in about 30% of DRE cases. Ultra-high field (UHF) MRI at 7T has shown improved lesion detection rates, but 9.4T MRI offers even higher spatial resolution and signal-to-noise ratio, albeit with increased technical challenges such as B1+ inhomogeneities and specific absorption rate (SAR) concerns. This study explores the feasibility and diagnostic value of 9.4T MRI in a DRE patient with negative findings at lower field strengths.
Data Highlights
Field Strength
Spatial Resolution (mm)
Scan Time (min)
Imaging Sequences
3T
0.9375 × 0.9375 × 0.9
Not specified
MPRAGE
7T
0.7 cubic
Not specified
MP2RAGE
9.4T
0.6 cubic
48
T1w MPRAGE, 3D GRE ASPIRE
Key Findings
9.4T MRI achieved a cubic spatial resolution of 0.6 mm, surpassing 3T and 7T resolutions.
Improved visualization and sharper delineation of the grey-white matter junction and mesiotemporal structures at 9.4T.
9.4T imaging was feasible with a total scan time of 48 minutes and no adverse events aside from transient dizziness.
Use of a 31-channel receive/16-channel parallel transmit coil and universal parallel transmit pulses mitigated B1+ inhomogeneity challenges at 9.4T.
9.4T MRI provided enhanced signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) in regions critical for epilepsy evaluation compared to lower field strengths.
Despite negative findings at 3T and 7T, 9.4T MRI offered superior anatomical detail potentially beneficial for pre-surgical assessment.
Clinical Implications
The enhanced spatial resolution and improved tissue contrast at 9.4T MRI may facilitate detection of subtle epileptogenic lesions not visible at lower field strengths, potentially expanding surgical candidacy in MRI-negative DRE patients. However, technical challenges such as B1+ inhomogeneity and SAR require specialized hardware and pulse design, underscoring the need for dedicated UHF MRI protocols and expertise. Integration of 9.4T imaging into clinical workflows could improve pre-surgical diagnostic accuracy and patient outcomes.
Conclusion
In vivo 9.4T MRI is technically feasible and provides superior anatomical detail in a patient with drug-resistant epilepsy previously MRI-negative at 3T and 7T. This advancement holds promise for enhancing lesion detection and guiding surgical treatment in challenging DRE cases.
References
de Boer et al. 2024 -- In Vivo 9.4 Tesla MRI Imaging in a Patient with Drug-Resistant Epilepsy: A Technical Overview
by Rick H. G. J. van Lanen, Daniel Uher, Desmond H. Y. Tse, Esther Steijvers, Albert J. Colon, Jacobus F. A. Jansen, Gerhard S. Drenthen, Dimo Ivanov, Govert Hoogland, Kim Rijkers, Christianne M. Hoeberigs, Paul A. M. Hofman, Walter H. Backes, Olaf E. M. G. Schijns
